Gursoy, P. Et Al. 2023. Real-life comparison of afatinib and erlotinib in non-small cell lung cancer with rare EGFR exon 18 and exon 20 mutations: a Turkish Oncology Group (TOG) study. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY , vol.149, no.2 , 865-875.

Gursoy, P., Tatli, A. M., Erdem, D., Goker, E., Celik, E., Demirci, N. S., ... Sakin, A.(2023). Real-life comparison of afatinib and erlotinib in non-small cell lung cancer with rare EGFR exon 18 and exon 20 mutations: a Turkish Oncology Group (TOG) study. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY , vol.149, no.2, 865-875.

Gursoy, Pinar Et Al. "Real-life comparison of afatinib and erlotinib in non-small cell lung cancer with rare EGFR exon 18 and exon 20 mutations: a Turkish Oncology Group (TOG) study," JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY , vol.149, no.2, 865-875, 2023

Gursoy, Pinar Et Al. "Real-life comparison of afatinib and erlotinib in non-small cell lung cancer with rare EGFR exon 18 and exon 20 mutations: a Turkish Oncology Group (TOG) study." JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY , vol.149, no.2, pp.865-875, 2023

Gursoy, P. Et Al. (2023) . "Real-life comparison of afatinib and erlotinib in non-small cell lung cancer with rare EGFR exon 18 and exon 20 mutations: a Turkish Oncology Group (TOG) study." JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY , vol.149, no.2, pp.865-875.

@article{article, author={Pinar Gursoy Et Al. }, title={Real-life comparison of afatinib and erlotinib in non-small cell lung cancer with rare EGFR exon 18 and exon 20 mutations: a Turkish Oncology Group (TOG) study}, journal={JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY}, year=2023, pages={865-875} }